Diabetes medication found to reduce heart failure deaths

Heart, failure

Popular diabetes medication has demonstrated a positive effect on the health of those suffering from heart failure.

A medication commonly used to treat diabetes, has shown positive effects in patients with heart failure. The medication reduces the patient’s risk of worsened heart failure or death from cardiovascular causes by more than 25%.

Approximately 920,616 people were suffering with heart failure in the UK alone, which is a 23% increase since 2002. Heart failure costs the National Health Service (NHS), UK, around €688M every single year. Due to the strain on the NHS, it is imperative that we find a way to reduce costs.

Research presented by scientists, from the University of Glasgow, at the European Society of Cardiology Congress 2019, found that the diabetes drug dapagliflozin could be used as a treatment for those suffering from heart failure.

Heart failure is a very common complication associated with type 2 diabetes; however, researchers have found dapaglifozin to reduce the patient’s risk of developing the condition.

The DAPA-HF trail assessed 4,744 patients, from 20 different countries. The effectiveness of dapaglifozin was then tested against a placebo in a group of suffers of diabetes and those who are not effected by the disease.

Professor John McMurray, Professor of Cardiology at the University of Glasgow, said: “These are really once in a lifetime findings, that show that a commonly prescribed drug for diabetes can effectively be used to treat people with heart failure.

“The results from DAPA-HF are remarkable – probably the most important finding of all is that dapagliflozin was associated with benefit in patients without diabetes. With dapagliflozin, we did the three things you want to do for the patient in the ideal world: make them feel better, keep them out of hospital and keep them alive. That’s why we’re so delighted with the results.”

Professor McMurray continued: “Patients with heart failure report worse quality of life than individuals with any other chronic condition. In this trial, when compared with placebo, patients who were treated with dapagliflozin had a clinically important improvement in health-related quality of life.”


Laboratory Supplies Directory - Now Live


Please enter your comment!
Please enter your name here